FAM13A polymorphism is associated with a usual interstitial pneumonia pattern in patients with systemic sclerosis-associated interstitial lung disease

被引:0
|
作者
Bernstein, Elana J. [1 ]
Boin, Francesco [2 ]
Elicker, Brett [3 ]
Luo, Yiming [1 ]
Ren, Yawen [4 ]
Zhang, Meng [5 ]
Varga, John [6 ]
Assassi, Shervin [5 ]
机构
[1] Columbia Univ, Irving Med Ctr, Vagelos Coll Phys & Surg, Dept Med,Div Rheumatol, New York, NY USA
[2] Cedars Sinai Med Ctr, Dept Med, Div Rheumatol, Los Angeles, CA USA
[3] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA
[4] Univ Colorado, Dept Med, Div Rheumatol, Denver, CO USA
[5] Univ Texas Hlth Sci Ctr Houston, UTHlth Houston, Dept Med, Div Rheumatol, Houston, TX USA
[6] Univ Michigan, Dept Internal Med, Div Rheumatol, Ann Arbor, MI USA
基金
美国国家卫生研究院;
关键词
systemic sclerosis; interstitial lung disease; usual interstitial pneumonia; FAM13A; MUC5B; IDIOPATHIC PULMONARY-FIBROSIS; PROMOTER POLYMORPHISM; SUSCEPTIBILITY; GENE; SCLERODERMA; LOCI;
D O I
10.1093/rheumatology/keae573
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The MUC58 promoter single nucleotide polymorphism (SNP) rs35705950 has been associated with idiopathic pulmonary fibrosis (IPF) and RA-related interstitial lung disease (ILD), but not with SSc-ILD. We hypothesized that the MUC58 promoter polymorphism or other IPF susceptibility loci are associated with an increased risk for the uncommon SSc-usual interstitial pneumonia (UIP) endophenotype, rather than SSc-ILD in general. Methods: We performed a cross-sectional study of SSc-ILD patients from four US Scleroderma Programs to investigate the frequency of MUC58 rs35705950 and 12 additional IPF susceptibility loci. SSc-ILD patients were stratified by high resolution chest CT (HRCT) imaging findings into UIP and non-UIP groups. Analysis of HRCTs performed by a thoracic radiologist blinded to participants' characteristics classified each scan as definite UIP, probable UIP, indeterminate or alternative diagnosis, according to American Thoracic Society criteria. Results: Four-hundred and eighty-nine SSc-ILD patients were included; 80% were female and 75% were White. Twenty-three (4.7%) patients had a definite UIP pattern. The MUC58 SNP rs35705950 was not associated with a definite UIP pattern in SSc-ILD. In contrast, patients carrying two copies of the IPF risk gene FAM13A minor allele rs2609255 had significantly higher odds of a definite UIP pattern compared with the other patterns (odds ratio 3.40, 95% CI 1.19-9.70), and compared with an alternative diagnosis (odds ratio 3.65, 95% CI 1.25-10.65). Conclusion: We demonstrated a novel association between FAM13A and SSc-UIP. Contrary to IPF and RA-ILD, the MUC58 promoter polymorphism was not associated with a definite UIP pattern in SSc-ILD.
引用
收藏
页数:6
相关论文
共 50 条
  • [11] Nintedanib for systemic sclerosis-associated interstitial lung disease
    Rahimi, Susan
    LANCET RESPIRATORY MEDICINE, 2020, 8 (02): : 136 - 136
  • [12] Deep-learning CT imaging algorithm to detect usual interstitial pneumonia pattern in patients with systemic sclerosis-associated interstitial lung disease: association with disease progression and survival
    Stock, Carmel J. W.
    Nan, Yang
    Fang, Yingying
    Kokosi, Maria
    Kouranos, Vasilios
    George, Peter M.
    Chua, Felix
    Jenkins, Gisli R.
    Devaraj, Anand
    Desai, Sujal R.
    Denton, Christopher P.
    Wells, Athol U.
    Walsh, Simon L. F.
    Renzoni, Elisabetta A.
    RHEUMATOLOGY, 2024,
  • [13] Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
    Hoffmann-Vold, Anna-Maria
    Allanore, Yannick
    Alves, Margarida
    Brunborg, Cathrine
    Airo, Paolo
    Ananieva, Lidia P.
    Czirjak, Laszlo
    Guiducci, Serena
    Hachulla, Eric
    Li, Mengtao
    Mihai, Carina
    Riemekasten, Gabriela
    Sfikakis, Petros P.
    Kowal-Bielecka, Otylia
    Riccardi, Antonella
    Distler, Oliver
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (02) : 219 - 227
  • [14] Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease
    Bergamasco, Aurore
    Hartmann, Nadine
    Wallace, Laura
    Verpillat, Patrice
    CLINICAL EPIDEMIOLOGY, 2019, 11 : 257 - 273
  • [15] Lung transplantation for systemic sclerosis-associated interstitial lung disease
    Le Pavec, J.
    Launay, D.
    Cottin, V.
    Reynaud-Gaubert, M.
    REVUE DES MALADIES RESPIRATOIRES, 2023, 40 : E73 - E79
  • [16] Rituximab treatment for systemic sclerosis-associated interstitial lung disease: a case series of 13 patients
    Morgan, Kelly
    Woollard, Charlotte
    Beinart, Dylan
    Host, Lauren, V
    Roddy, Janet
    INTERNAL MEDICINE JOURNAL, 2023, 53 (07) : 1147 - 1153
  • [17] Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
    Chung, Jonathan H.
    Walker, Christopher M.
    Hobbs, Stephen
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2020, (160): : na
  • [18] Personalized Medicine for Systemic Sclerosis-Associated Interstitial Lung Disease
    Ma, Angela
    Montesi, Sydney B.
    CURRENT TREATMENT OPTIONS IN RHEUMATOLOGY, 2025, 11 (01)
  • [19] Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease REPLY
    Distler, Oliver
    Gahlemann, Martina
    Maher, Toby M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (16): : 1596 - 1597
  • [20] Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease
    Athanasios Koutroumpas
    Athanasios Ziogas
    Ioannis Alexiou
    Georgia Barouta
    Lazaros I. Sakkas
    Clinical Rheumatology, 2010, 29 : 1167 - 1168